Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Keros Therapeutics (KROS) Shares Outstanding (Diluted Average) (2020 - 2025)

Historic Shares Outstanding (Diluted Average) for Keros Therapeutics (KROS) over the last 6 years, with Q3 2025 value amounting to $41.2 million.

  • Keros Therapeutics' Shares Outstanding (Diluted Average) rose 960.78% to $41.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $41.2 million, marking a year-over-year increase of 960.78%. This contributed to the annual value of $37.4 million for FY2024, which is 2713.52% up from last year.
  • As of Q3 2025, Keros Therapeutics' Shares Outstanding (Diluted Average) stood at $41.2 million, which was up 960.78% from $41.2 million recorded in Q2 2025.
  • In the past 5 years, Keros Therapeutics' Shares Outstanding (Diluted Average) registered a high of $41.2 million during Q3 2025, and its lowest value of $23.2 million during Q1 2021.
  • Moreover, its 5-year median value for Shares Outstanding (Diluted Average) was $29.4 million (2023), whereas its average is $30.5 million.
  • Its Shares Outstanding (Diluted Average) has fluctuated over the past 5 years, first skyrocketed by 5047.93% in 2021, then surged by 321.08% in 2022.
  • Quarter analysis of 5 years shows Keros Therapeutics' Shares Outstanding (Diluted Average) stood at $23.3 million in 2021, then rose by 8.17% to $25.2 million in 2022, then rose by 16.66% to $29.4 million in 2023, then rose by 27.14% to $37.4 million in 2024, then rose by 10.06% to $41.2 million in 2025.
  • Its Shares Outstanding (Diluted Average) was $41.2 million in Q3 2025, compared to $41.2 million in Q2 2025 and $41.0 million in Q1 2025.